PSMAddition: Does Earlier Really Mean Better?
The Drug Is Ready for the Clinic. The Manuscript Is Still Missing.
Beyond The Abstract: Urology
Evidence without Agenda
Live Last read · last published · next check
Latest episodes
PROTEUS trial
A trial that raises more questions than it answers.
Metformin and Prostate Cancer: The Tale Continues
From observational promise to consistent negative randomized evidence
Beyond the Abstract: EV-303 (KEYNOTE-905)
Practice-changing results — but there is a problem after progression
PEACE-3 — Does Earlier Radium-223 Actually Matter?
Post-progression therapy suggests limited use of radium-223 in the control arm
Oxybutynin to treat Hot Flushes in Prostate Cancer
Cooling the Heat Without Heating the Budget
Ultra-hypofractinated radiotherapy in prostate cancer
Prospective 10-Year Radiotherapy Data Show Higher-Than-Expected Toxicity—And We Still Await the Patient Voice
PSA for Prostate Cancer Screening: How ERSPC confirms the importance of active surveillance
Interpreting the 23 year ERSPC results in the era of MRI, risk stratification, and active surveillance
IMvigor011: A Biology-Guided Approach to Adjuvant Immunotherapy
Solid trial, but don't call it "adjuvant"
IO & Prostate cancer: When Two Phase III Trials Answer the Same Question—and the Answer Is “No”
Spoiler alert: no room for checkpoint inhibitors in metastatic prostate cancer!
TALAPRO-2: a strong trial, a real survival gain, but at the cost of high toxicity
A strong case for intensification, without closing the sequencing debate
A First Year of Looking Beyond the Abstract: 2025 in Urology Trials
Looking back at 2025, one pattern stands out: a year full of anticipation, but light on true game-changers.
CREST Trial: Positivity by Redesign, Ethical Concerns in Treatment Allocation, and Industry-Controlled Safety Signals
Another "Game Changer" with major limitations
CAPItello-281 phase III study: Not a Game Changer at all in prostate cancer treatment
A closer look at why capivasertib fails to deliver meaningful benefit in PTEN-deficient mHSPC
SEXTANT-PRO: A Clean Non-Inferiority Trial With Practice-Changing Potential
In MRI-positive patients, accuracy may not come from more sampling — but from smarter sampling.
Metformin in Active Surveillance: A Simple Question, a Clear Answer
Spoiler alert: negative results are also results, which lead to progress
Urothelial Cancer Breakthrough: Beyond the RC48-C016 Abstract
Disitamab Vedotin + Toripalimab in HER2-Expressing Advanced Urothelial Cancer - New England Journal of Medicine, October 2025
The AMPLITUDE Trial — PARP Inhibition Moves Upstream in HRR-Deficient mCSPC
Johnson & Johnson want Niraparib in the hormone-sensitive BRCA-altered prostate cancer setting based on PFS — efficacy signal, but fundamental design flaws remain.
EMBARK Final Results: OS benefit with a catch
Do we have enough data to defend the use of Enzalutamide in the Biochemical Recurrence setting?
POTOMAC: A Closer Look at Durvalumab in BCG-Naive NMIBC
The POTOMAC trial results are out — presented at ESMO and now published in The Lancet.